Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)

Hdl Handle:
http://hdl.handle.net/10144/618745
Title:
Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)
Authors:
Henao-Restrepo, AM; Camacho, A; Longini, IM; Watson, CH; Edmunds, WJ; Egger, M; Carroll, MW; Dean, NE; Diatta, I; Doumbia, M; Draguez, B; Duraffour, S; Enwere, G; Grais, R; Gunther, S; Gsell, PS; Hossmann, S; Watle, SV; Kondé, MK; Kéïta, S; Kone, S; Kuisma, E; Levine, MM; Mandal, S; Mauget, T; Norheim, G; Riveros, X; Soumah, A; Trelle, S; Vicari, AS; Røttingen, JA; Kieny, MP
Journal:
Lancet (London, England)
Abstract:
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.
Publisher:
Elsevier
Issue Date:
23-Dec-2016
URI:
http://hdl.handle.net/10144/618745
DOI:
10.1016/S0140-6736(16)32621-6
PubMed ID:
28017403
Submitted date:
2017-01-11
Language:
en
ISSN:
1474-547X
Appears in Collections:
Other Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorHenao-Restrepo, AMen
dc.contributor.authorCamacho, Aen
dc.contributor.authorLongini, IMen
dc.contributor.authorWatson, CHen
dc.contributor.authorEdmunds, WJen
dc.contributor.authorEgger, Men
dc.contributor.authorCarroll, MWen
dc.contributor.authorDean, NEen
dc.contributor.authorDiatta, Ien
dc.contributor.authorDoumbia, Men
dc.contributor.authorDraguez, Ben
dc.contributor.authorDuraffour, Sen
dc.contributor.authorEnwere, Gen
dc.contributor.authorGrais, Ren
dc.contributor.authorGunther, Sen
dc.contributor.authorGsell, PSen
dc.contributor.authorHossmann, Sen
dc.contributor.authorWatle, SVen
dc.contributor.authorKondé, MKen
dc.contributor.authorKéïta, Sen
dc.contributor.authorKone, Sen
dc.contributor.authorKuisma, Een
dc.contributor.authorLevine, MMen
dc.contributor.authorMandal, Sen
dc.contributor.authorMauget, Ten
dc.contributor.authorNorheim, Gen
dc.contributor.authorRiveros, Xen
dc.contributor.authorSoumah, Aen
dc.contributor.authorTrelle, Sen
dc.contributor.authorVicari, ASen
dc.contributor.authorRøttingen, JAen
dc.contributor.authorKieny, MPen
dc.date.accessioned2017-01-12T20:59:38Z-
dc.date.available2017-01-12T20:59:38Z-
dc.date.issued2016-12-23-
dc.date.submitted2017-01-11-
dc.identifier.citationEfficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!). 2016 Lanceten
dc.identifier.issn1474-547X-
dc.identifier.pmid28017403-
dc.identifier.doi10.1016/S0140-6736(16)32621-6-
dc.identifier.urihttp://hdl.handle.net/10144/618745-
dc.description.abstractrVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Lancet (London, England)en
dc.titleEfficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)en
dc.identifier.journalLancet (London, England)en

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.